| Name: | Axitinib Tetrahydropyran Impurity |
| Catalogue No. | VE006371 |
| CAS No. | 2242852-05-5 |
| Molecular Formula | C19H19N3O |
| Molecular Weight | 305.37 |
| Status | In-stock |
| IUPAC Name | 3-[(1E)-2-(2-Pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole |
| Description | Axitinib Tetrahydropyran Impurity(CAS No: 2242852-05-5) or 3-[(1E)-2-(2-Pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, Axitinib Tetrahydropyran Impurity is an impurity of Axitinib Tetrahydropyran, it is a second-generation targeted drug that is used to treat advanced renal cell carcinoma. |
| References | Chen, Ying, et al. “Clinical Pharmacology of Axitinib.” Clinical Pharmacokinetics, vol. 52, no. 9, 1 Sept. 2013, pp. 713–725, link.springer.com/article/10.1007%2Fs40262-013-0068-3, 10.1007/s40262-013-0068-3. Accessed 6 May 2021. |
